total hip arthroplasty
Conditions
Interventions
A Group (Ropivacaine Group):Application of 100mg:25ml (0.4%) ropivacaine pericapsular nerve group(PENG) block combined with lateral femoral cutaneous nerve block
B Group (Bupivacaine Liposome Group):Application of 266mg:25ml (1.06%)bupivacaine liposome pericapsular nerve group(PENG) block combined with lateral femoral cutaneous nerve block
B2 Group ( liposomal bupivacaine combined with bupivacainehydrochloride group):PENG block combined with lateral femoral cutaneous nerveblockwas performed with bupivacaine liposome 266 mgmixedwith0.75%
Sponsors
The First Affiliated Hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Aged >= 18 years. 2. American Society of Anesthesiologists (ASA) classification I-III. 3.NYHA classification of cardiac function I-II. 4. Body mass index (BMI) is 18-30 kg·m^2.
Exclusion criteria
Exclusion criteria: 1. Infection at the injection site. 2. Patients have severe arrhythmias or cardiovascular disease, liver and kidney dysfunction, respiratory and coagulation disorders. 3. Continue to take pain relievers in the near future. 4. Having trouble communicating and not being able to complete the scores properly. 5. I or its authorized person does not accept, can not cooperate with block patients have.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analog Scale (VAS) scores;quality of recovery-15 scale (QoR-15); | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative adverse events; | — |
Countries
China
Contacts
Public ContactHeng Rong
The First Affiliated Hospital of Guangxi Medical University
Outcome results
None listed